News Conference News ACC 2024 KARDIA-2: Zilebesiran Drops BP on Top of Common Antihypertensives Shelley Wood April 11, 2024
News Conference News ACC 2020 Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds Todd Neale March 25, 2020
News Conference News ACC 2019 First Ticagrelor Reversal Agent Shows Quick Onset, Long Duration in Early Results Yael L. Maxwell March 25, 2019
News Conference News ISC 2019 Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects Todd Neale February 13, 2019
News Conference News ACC 2018 My Takeaways From ACC 2018: Everyone Missing From Clinical Trials, Please Stand Up Shelley Wood March 27, 2018
News Conference News ACC 2018 Reversal Agent for Factor Xa Inhibitors Continues to Look Good: ANNEXA-4 Todd Neale March 13, 2018
News Conference News ACC 2018 ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More Shelley Wood March 12, 2018
News Conference News VIVA 2017 Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients L.A. McKeown September 11, 2017
News Conference News ACC 2017 RE-CIRCUIT: Doubts Over Dabigatran for A-fib Ablations Put to Rest Yael L. Maxwell March 20, 2017
News Conference News ISC 2017 NOAC-Related Intracranial Hemorrhages May Not Be as Bad as Those Stemming From Warfarin Todd Neale March 01, 2017
News Conference News AHA 2016 Misdosing NOACs Common in Everyday Practice, With Implications for Stroke and Bleeding Shelley Wood November 21, 2016
News Conference News ESC 2016 Reversal Agent for Factor Xa Inhibitors Rapidly Reduces Anticoagulant Effects: ANNEXA-4 Todd Neale August 31, 2016
News Conference News AHA 2015 Reversal Agents Safely Stop Effects of Novel Oral Anticoagulants Yael L. Maxwell November 10, 2015
News Conference News ESC 2012 Stem Cells, Nanoparticles Appear to be an Antidote to Atherosclerosis Caitlin E. Cox August 29, 2012